Reversal of target-specific oral anticoagulants

Area of Science:

• Pharmacology
• Hematology
• Internal Medicine

Background:

• Target-specific oral anticoagulants (TSOAs) are novel antithrombotic agents offering therapeutic advantages.
• Unlike warfarin, TSOAs lack specific reversal antidotes, posing clinical challenges.
• Serious bleeding or emergent surgery necessitates effective anticoagulation reversal strategies.

Purpose of the Study:

• To review existing data on non-specific therapies for reversing TSOAs.
• To prepare clinicians for managing patients on dabigatran, rivaroxaban, or apixaban requiring urgent intervention.
• To address the critical need for reversal methods in TSOA therapy.

Main Methods:

• Literature review of studies investigating non-specific reversal agents for TSOAs.
• Analysis of data concerning the efficacy and safety of prohemostatic therapies.
• Focus on agents like dabigatran, rivaroxaban, and apixaban.

Main Results:

• Limited data exists on the effectiveness of non-specific reversal agents.
• Prohemostatic therapies show variable and incompletely understood mechanisms of action.
• No universally accepted protocol for TSOA reversal is established.

Conclusions:

• Clinicians must be prepared for managing bleeding or surgical emergencies in patients on TSOAs.
• Non-specific therapies are currently the primary, albeit imperfect, option for reversal.
• Further research is crucial to develop specific and reliable reversal agents for TSOAs.